BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.

The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.

Detailed study results will be presented at an upcoming medical meeting and submitted to health authorities later this year to expand Palynziq’s label to include adolescents.

Higher prevalence ratios for misuse, prescription stimulant use disorder seen for those using amphetamines vs methylphenidate.

HealthDay News — Some commonly prescribed photosensitizing drugs increase skin cancer risk, according to a study published online March 18 in Photodermatology, Photoimmunology & Photomedicine.

The device was tested on a 47-year-old woman with quadriplegia who lost her ability to speak after a stroke. Doctors placed the brain-computer implant during surgery as part of a clinical trial, The ...

The DapaTAVI trial assessed the benefits of dapagliflozin in patients discharged after TAVI with a history of heart failure plus 1 of the following comorbidities: LVEF ≤40%, diabetes, or renal ...

The Food and Drug Administration (FDA) has cleared the Visby Medical Women’s Sexual Health Test for use at home to test for ...

Tovecimig, formerly known as CTX-009, is a bispecific antibody that blocks the Delta-like ligand 4 and vascular endothelial growth factor A signaling pathways.

The supplemental New Drug Application for the C3G and IC-MPGN indications is supported by data from the phase 3 VALIANT study.

The live vaccine is produced from the strain Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN), an attenuated, non-replicating orthopoxvirus.

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT 1A agonist. It is currently approved under the brand name Sunosi ® to improve ...